Thrombectomy 24 hours after stroke: beyond DAWN
| Autor: | Roberta Santos, Diogo C Haussen, Ashutosh P Jadhav, Amin Aghaebrahim, Tudor G Jovin, Alhamza R Al-Bayati, Raul G Nogueira, Shashvat M Desai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Time Factors 030204 cardiovascular system & hematology Brain Ischemia 03 medical and health sciences 0302 clinical medicine Fibrinolytic Agents Modified Rankin Scale Humans Medicine In patient Prospective Studies Stroke Acute ischemic stroke Aged Retrospective Studies Thrombectomy Aged 80 and over Retrospective review business.industry Endovascular Procedures General Medicine Middle Aged medicine.disease Surgery Treatment Outcome Baseline characteristics Functional independence Female Neurology (clinical) business Intracranial Hemorrhages 030217 neurology & neurosurgery Large vessel occlusion |
| Zdroj: | Journal of NeuroInterventional Surgery. 10:1039-1042 |
| ISSN: | 1759-8486 1759-8478 |
| Popis: | Background and purposeThe results of the DAWN trial support the benefit of thrombectomy in patients with anterior circulation large vessel occlusion (LVO) acute stroke presenting within 6–24 hours from time last known well (TLKW). We sought to evaluate the characteristics and outcomes of patients who met DAWN criteria but underwent thrombectomy beyond 24 hours of TLKW.MethodsA retrospective review of endovascular thrombectomy databases at three comprehensive stroke centers was performed to identify all patients who received thrombectomy beyond 24 hours of TLKW and otherwise met the DAWN criteria. Baseline characteristics, efficacy, and safety outcomes were compared with patients in the DAWN trial intervention arm.ResultsTwenty-one patients met the inclusion criteria. Rates of successful reperfusion (mTICI2b–3: 81% vs 84%, P=0.72), 90-day functional independence (modified Rankin Scale score 0–2, 43% vs 48%, P=0.68), and symptomatic intracranial hemorrhage (5% vs 6%, P=0.87) were comparable across the two groups.ConclusionThrombectomy appears to be safe and feasible in patients with acute ischemic stroke due to LVO meeting all DAWN trial criteria but treated beyond 24 hours of TLKW with outcomes comparable to patients in the DAWN trial intervention arm. Further studies are warranted to validate these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|